Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2007–2009.

https://doi.org/10.1182/blood-2022-157210

Published: 2022

Journal Articles

Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

Blood (2022) 140 (Supplement 1): 8973–8975.

https://doi.org/10.1182/blood-2022-157323

Published: 2022

Journal Articles

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Blood (2022) 140 (Supplement 1): 8966–8968.

https://doi.org/10.1182/blood-2022-157358

Published: 2022

Journal Articles

A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)

Jayastu Senapati, Farhad Ravandi, Courtney D. DiNardo, Ghayas C. Issa, Koji Sasaki, Marina Konopleva, Naveen Pemmaraju, Kelly S. Chien, Maro Ohanian, Elias Jabbour, Abhishek Maiti, Edith Roy, Ricardo Delumpa, Juan Rivera, Christopher Loiselle, Glenda Banks, Hagop Kantarjian, Nicholas Short

Blood (2022) 140 (Supplement 1): 3880–3882.

https://doi.org/10.1182/blood-2022-170773

Published: 2022

Journal Articles

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

Blood (2022) 140 (Supplement 1): 513–515.

https://doi.org/10.1182/blood-2022-157775

Published: 2022

Journal Articles

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Blood (2022) 140 (Supplement 1): 6206–6208.

https://doi.org/10.1182/blood-2022-165359

Published: 2022

Journal Articles

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 2298.

https://doi.org/10.1182/blood-2021-153795

Published: 2021

Journal Articles

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 696.

https://doi.org/10.1182/blood-2021-153571

Published: 2021

Journal Articles

Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 2349.

https://doi.org/10.1182/blood-2021-153682

Published: 2021

Journal Articles

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)

Guillaume Richard-Carpentier, MD, Amy E. DeZern, MD, Koichi Takahashi, MD, Marina Y Konopleva, MD PhD, Sanam Loghavi, MD, Lucia Masarova, MD, Yesid Alvarado, MD, Farhad Ravandi, MD, Guillermo Montalban Bravo, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Ricardo Delumpa, BSN, Monica Kwari, BSN, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD, Gail J. Roboz, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 678.

https://doi.org/10.1182/blood-2019-130501

Published: 2019

Journal Articles

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Michael R. Kurman, MD, Courtney D. DiNardo, MD MSc, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Kiran Naqvi, MD MPH, Farhad Ravandi, MD, Elias J. Jabbour, MD, Ricardo Delumpa, BSN, Timothy Madden, PhD, Gary Maier, PhD, Hiroyuki Iwamura, PhD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 1438.

https://doi.org/10.1182/blood-2018-99-116613

Published: 2018

Journal Articles

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Blood (2016) 128 (22): 1640.

https://doi.org/10.1182/blood.V128.22.1640.1640

Published: 2016

Journal Articles

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Guillermo Garcia-Manero, MD, Hui Yang, MD PhD, Zhihong Fang, Courtney DiNardo, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Ricardo Delumpa, RN, Christopher Loiselle, RN, Susan Denton, RN, Whitney Smith, Hiroyuki Iwamura, PhD, Teletha Gipson, PhD, Michele Rosner, MS, Timothy Madden, PharmD, Thomas J. Myers, MD, Linda J. Paradiso, DVM, MBA

Blood (2015) 126 (23): 3800.

https://doi.org/10.1182/blood.V126.23.3800.3800

Published: 2015

NARROW

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia

Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only